Study Summary
This trial will study a new combination therapy for patients with lung cancer who have progressed despite previous treatment with a similar drug.
- Metastatic Cancers
- Malignant Neoplasms
- Malignant Neoplastic Disease
- Non-Small Cell Lung Carcinoma (NSCLC)
- KRAS Activating Mutation
- Cancer, Advanced
Treatment Effectiveness
Study Objectives
3 Primary · 13 Secondary · Reporting Duration: Up to 5 years
Trial Safety
Trial Design
4 Treatment Groups
Avutometinib(VS-6766)+adagrasib
1 of 4
Avutometinib (VS-6766)+adagrasib RP2D
1 of 4
VS-6766+adagrasib
1 of 4
VS-6766+adagrasib RP2D
1 of 4
Experimental Treatment
85 Total Participants · 4 Treatment Groups
Primary Treatment: VS-6766 and adagrasib · No Placebo Group · Phase 1 & 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:About The Reviewer
Michael Gill - B. Sc.
First Published: October 11th, 2021
Last Reviewed: November 1st, 2022
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.